Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52674#.VKC5YcCAM4 Author(s) A. Prica 1 , A. Pratzer 2 , M. Cheung 1 , K. Thompson 3 , E. Piliotis 1 , N. L. Berinstein 1 , K. Imrie 1 , R. Pradhan 4 , A. Vyas 4 , Z. Ghorab 4 , D. Good 4 , L. Zhang 1 , R. Buckstein 1* Affiliation(s) 1 Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada . 2 Feinberg School of Medicine, Northwestern University, Chicago, USA . 3 Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada . 4 Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada . ABSTRACT Background: Dose-modified (dm) CODOX-M/IVAC...